Amgen Drops 7% After A 'Big, Unknown Risk' Rattles Obesity Shot

By Investor's Business Daily   |   2 years ago
Amgen Drops 7% After A 'Big, Unknown Risk' Rattles Obesity Shot

Amgen's stock fell due to concerns about MariTide's impact on bone mineral density. Analysts remain optimistic but acknowledge risks. Amgen's weight-loss shot faces competition from Novo Nordisk and Eli Lilly. Pfizer is also developing a similar drug.

Read More

Did you find this insightful?